Brief: Gyre Therapeutics Inc Received A Letter From Nasdaq That It Had Regained Compliance With Nasdaq Listing Rule 5605 On March 22
26/03/2024 21:18
March 26 (Reuters) - Gyre Therapeutics Inc GYRE.O :
* GYRE THERAPEUTICS INC- ON MARCH 22 RECEIVED A LETTER FROM
NASDAQ THAT IT HAD REGAINED COMPLIANCE WITH NASDAQ LISTING RULE
5605
Source text for Eikon: ID:n0001140361-24-015318
Further company coverage: GYRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes